New
HealthMore in Health→
Eplontersen benefit appears limited to ATTR-CM patients not already on stabilizers
Key Takeaways
- A prespecified CARDIO-TTRansform analysis found eplontersen's effect differed by baseline stabilizer use.
- Patients not on stabilizers showed benefit on the primary composite endpoint, while those already on stabilizers did not.
- The findings challenge the assumption that adding a gene silencer to stabilizer therapy automatically improves outcomes.
DE
DT Editorial Team··via nature.com